Humanwell Healthcare’s HW221043 Receives NMPA Approval for Advanced Solid Tumor Trials
Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its independently developed HW221043 tablets have...
Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement...
Frontier Biotech’s FB7013 Wins NMPA IND for MASP‑2 siRNA in IgA Nephropathy
Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND)...
Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal
Insilico Medicine (HKG: 3696) announced a multi‑year R&D collaboration with Servier to identify and develop...
Kelun-Biotech’s sac-TMT Wins Breakthrough Therapy Designation for First‑Line NSCLC
Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac‑TMT, SKB264/MK‑2870), its TROP2‑directed...
Kangtai Biological Co‑founds Beijing Laboratory to Advance Synthetic Immunology and Vaccine Manufacturing
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that its wholly‑owned subsidiary Minhai Biotechnology...
Kelun-Biotech’s ITGB6 ADC SKB105 Wins NMPA IND Approval
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Investigational New Drug (IND) application...
Huadong Medicine Licenses MC2’s PAD‑Based Biomee Skincare for Greater China
Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly‑owned...
CMS Unveils BALANCE Model to Expand GLP-1 Access for Medicare/Medicaid
The U.S. Centers for Medicare & Medicaid Services (CMS) unveiled the BALANCE Model (Better Approaches...
GenEditBio’s GEB-101 Wins FDA IND Approval as World’s First Corneal Gene Therapy
GenEditBio announced that GEB-101, its self‑developed in vivo genome editing investigational drug, has received Investigational...
Merck’s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world’s...
Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
Aspen Holdings announced a binding agreement for its wholly‑owned subsidiary Aspen Global Incorporated (AGI) to...
China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
The National Medical Products Administration (NMPA) announced that China approved 76 innovative drugs for marketing...
China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
Novo Nordisk (NYSE: NVO) announced that China’s Supreme People’s Court upheld the Beijing IP Court ruling,...
Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical...
Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio
Genmab A/S (NASDAQ: GMAB) announced it will discontinue clinical development of acasunlimab, a PD‑L1 x...
NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support
The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged...
Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy
Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making...
China State Council Approves Revised Drug Administration Regulations, Accelerating Innovation Review
The State Council of China approved the Revised Draft of the Implementation Regulations of the...
Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced a licensing agreement with Adlai Nortye Ltd...